Aytu BioPharma Q4 EPS $0.00 and Sales $16.106M Beat $12.276M Estimate

Aytu BioPharma (NASDAQ: AYTU) reported Q4 sales of $16.106 million, exceeding the analyst consensus estimate of $12.276 million by 31.20%. This represents a 6.42% increase compared to sales of $15.135 million in the same period last year. The company's earnings per share (EPS) for the quarter was reported at $0.00.